American Portfolios Advisors’s Insight Molecular Diagnostics IMDX Stock Holding History

American Portfolios Advisors’s Portfolio IMDX Stock Details IMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$15.9K	Hold	1,092	–	–	﹤0.01%	2300
2022 Q2	$19.6K	Buy	1,092 +500	+84%	+$11.4K	﹤0.01%	2239
2022 Q1	$17.6K	Sell	592 -30	-5%	-$959	﹤0.01%	2436
2021 Q4	$27K	Sell	622 -2	-0.3%	-$115	﹤0.01%	2192
2021 Q3	$44.4K	Hold	624	–	–	﹤0.01%	1837
2021 Q2	$71.6K	Hold	624	–	–	﹤0.01%	1549
2021 Q1	$64.8K	Buy	624 +594	+1,980%	+$56.4K	﹤0.01%	1489
2020 Q4	$1.43K	Sell	30 -3	-9%	-$110	﹤0.01%	2771
2020 Q3	$910	Sell	33 -110	-77%	-$3.15K	﹤0.01%	2780
2020 Q2	$5.45K	Hold	143	–	–	﹤0.01%	2203
2020 Q1	$7K	Buy	143 +75	+110%	+$3.68K	﹤0.01%	1956
2019 Q4	$3.05K	Hold	68	–	–	﹤0.01%	2452
2019 Q3	$2.85K	Buy	+68	New	+$2.67K	﹤0.01%	2400

Other funds holding IMDX

Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return

PVI

Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

American Portfolios Advisors's IMDX Position: Q3 2022 in Review

American Portfolios Advisors held its Insight Molecular Diagnostics (IMDX) position steady in Q3 2022 at 1,092 shares worth $15.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2300.

American Portfolios Advisors first reported a position in IMDX in Q3 2019 and has held it in 13 quarters since. The position peaked at $71.6K in Q2 2021. 65 funds tracked by Wall St. Rank hold IMDX as of Q3 2022.

American Portfolios Advisors held 1,092 shares of Insight Molecular Diagnostics worth $15.9K as of Q3 2022.
American Portfolios Advisors left its Insight Molecular Diagnostics share count unchanged in Q3 2022.
Insight Molecular Diagnostics made up ﹤0.01% of American Portfolios Advisors's portfolio in Q3 2022, its #2300 holding.
American Portfolios Advisors first reported a position in Insight Molecular Diagnostics in Q3 2019 and has held it in 13 quarters since.
American Portfolios Advisors's Insight Molecular Diagnostics position peaked at $71.6K in Q2 2021.
65 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2022.

Based on American Portfolios Advisors's 13F filing for Q3 2022, filed 17 Mar 2023.